Suppr超能文献

实现反相蛋白质阵列在临床、转化和基础研究中的前景:研讨会报告:反相蛋白质阵列协会

Realizing the promise of reverse phase protein arrays for clinical, translational, and basic research: a workshop report: the RPPA (Reverse Phase Protein Array) society.

作者信息

Akbani Rehan, Becker Karl-Friedrich, Carragher Neil, Goldstein Ted, de Koning Leanne, Korf Ulrike, Liotta Lance, Mills Gordon B, Nishizuka Satoshi S, Pawlak Michael, Petricoin Emanuel F, Pollard Harvey B, Serrels Bryan, Zhu Jingchun

机构信息

From the *University of Texas M.D. Anderson Cancer Center, Houston, Texas;

‡Technische Universität München, München, Germany;

出版信息

Mol Cell Proteomics. 2014 Jul;13(7):1625-43. doi: 10.1074/mcp.O113.034918. Epub 2014 Apr 28.

Abstract

Reverse phase protein array (RPPA) technology introduced a miniaturized "antigen-down" or "dot-blot" immunoassay suitable for quantifying the relative, semi-quantitative or quantitative (if a well-accepted reference standard exists) abundance of total protein levels and post-translational modifications across a variety of biological samples including cultured cells, tissues, and body fluids. The recent evolution of RPPA combined with more sophisticated sample handling, optical detection, quality control, and better quality affinity reagents provides exquisite sensitivity and high sample throughput at a reasonable cost per sample. This facilitates large-scale multiplex analysis of multiple post-translational markers across samples from in vitro, preclinical, or clinical samples. The technical power of RPPA is stimulating the application and widespread adoption of RPPA methods within academic, clinical, and industrial research laboratories. Advances in RPPA technology now offer scientists the opportunity to quantify protein analytes with high precision, sensitivity, throughput, and robustness. As a result, adopters of RPPA technology have recognized critical success factors for useful and maximum exploitation of RPPA technologies, including the following: preservation and optimization of pre-analytical sample quality, application of validated high-affinity and specific antibody (or other protein affinity) detection reagents, dedicated informatics solutions to ensure accurate and robust quantification of protein analytes, and quality-assured procedures and data analysis workflows compatible with application within regulated clinical environments. In 2011, 2012, and 2013, the first three Global RPPA workshops were held in the United States, Europe, and Japan, respectively. These workshops provided an opportunity for RPPA laboratories, vendors, and users to share and discuss results, the latest technology platforms, best practices, and future challenges and opportunities. The outcomes of the workshops included a number of key opportunities to advance the RPPA field and provide added benefit to existing and future participants in the RPPA research community. The purpose of this report is to share and disseminate, as a community, current knowledge and future directions of the RPPA technology.

摘要

反相蛋白质阵列(RPPA)技术引入了一种小型化的“抗原向下”或“斑点印迹”免疫测定法,适用于定量各种生物样品(包括培养细胞、组织和体液)中总蛋白水平和翻译后修饰的相对、半定量或定量(如果存在公认的参考标准)丰度。RPPA的最新发展与更复杂的样品处理、光学检测、质量控制以及质量更好的亲和试剂相结合,以合理的每份样品成本提供了出色的灵敏度和高样品通量。这有助于对来自体外、临床前或临床样品的多个样品中的多种翻译后标记物进行大规模多重分析。RPPA的技术力量正在推动RPPA方法在学术、临床和工业研究实验室中的应用和广泛采用。RPPA技术的进步现在为科学家提供了高精度、高灵敏度、高通量和稳健性地定量蛋白质分析物的机会。因此,RPPA技术的采用者已经认识到有效且最大程度利用RPPA技术的关键成功因素,包括以下几点:分析前样品质量的保存和优化、经过验证的高亲和力和特异性抗体(或其他蛋白质亲和力)检测试剂的应用、确保蛋白质分析物准确且稳健定量的专用信息学解决方案,以及与受监管临床环境中的应用兼容的质量保证程序和数据分析工作流程。2011年、2012年和2013年,前三届全球RPPA研讨会分别在美国、欧洲和日本举行。这些研讨会为RPPA实验室人员、供应商和用户提供了分享和讨论结果、最新技术平台、最佳实践以及未来挑战与机遇的机会。研讨会的成果包括推进RPPA领域并为RPPA研究社区的现有和未来参与者提供更多益处的一些关键机遇。本报告的目的是作为一个群体分享和传播RPPA技术的当前知识和未来方向。

相似文献

2
Reverse Phase Protein Arrays.
Methods Mol Biol. 2021;2237:103-122. doi: 10.1007/978-1-0716-1064-0_9.
4
5
Signaling pathway profiling by reverse-phase protein array for personalized cancer medicine.
Biochim Biophys Acta. 2015 Jun;1854(6):651-7. doi: 10.1016/j.bbapap.2014.10.014. Epub 2014 Oct 27.
6
Semi-quantitative measurement of specific proteins in human cumulus cells using reverse phase protein array.
Reprod Biol Endocrinol. 2013 Oct 22;11:100. doi: 10.1186/1477-7827-11-100.
7
Profiling Glycoproteins on Functionalized Reverse Phase Protein Array.
Methods Mol Biol. 2021;2237:207-215. doi: 10.1007/978-1-0716-1064-0_17.
8
Reverse Phase Protein Arrays and Drug Discovery.
Methods Mol Biol. 2017;1647:153-169. doi: 10.1007/978-1-4939-7201-2_10.
9
Reproducibility and Crossplatform Validation of Reverse-Phase Protein Array Data.
Adv Exp Med Biol. 2019;1188:181-201. doi: 10.1007/978-981-32-9755-5_10.

引用本文的文献

2
Patient-derived organotypic tissue cultures as a platform to evaluate metabolic reprogramming in breast cancer patients.
J Biol Chem. 2025 May;301(5):108495. doi: 10.1016/j.jbc.2025.108495. Epub 2025 Apr 8.
6
Proteomics based selection achieves complete response to HER2 therapy in HER2 IHC 0 breast cancer.
NPJ Precis Oncol. 2024 Sep 14;8(1):203. doi: 10.1038/s41698-024-00696-6.
8
A prognostic matrix gene expression signature defines functional glioblastoma phenotypes and niches.
Res Sq. 2024 Jun 21:rs.3.rs-4541464. doi: 10.21203/rs.3.rs-4541464/v1.
9
Quantitative proteomic analysis of HER2 protein expression in PDAC tumors.
Clin Proteomics. 2024 Mar 20;21(1):24. doi: 10.1186/s12014-024-09476-7.
10
Harnessing the potential of reverse-phase protein array technology: Advancing precision oncology strategies.
Cancer Sci. 2024 May;115(5):1378-1387. doi: 10.1111/cas.16123. Epub 2024 Feb 26.

本文引用的文献

1
Application of molecular technologies for phosphoproteomic analysis of clinical samples.
Oncogene. 2015 Feb 12;34(7):805-14. doi: 10.1038/onc.2014.16. Epub 2014 Mar 10.
3
Glioblastoma cell enrichment is critical for analysis of phosphorylated drug targets and proteomic-genomic correlations.
Cancer Res. 2014 Feb 1;74(3):818-28. doi: 10.1158/0008-5472.CAN-13-2172. Epub 2013 Dec 17.
4
Neuregulin autocrine signaling promotes self-renewal of breast tumor-initiating cells by triggering HER2/HER3 activation.
Cancer Res. 2014 Jan 1;74(1):341-52. doi: 10.1158/0008-5472.CAN-13-1055. Epub 2013 Oct 31.
5
Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer.
Clin Cancer Res. 2013 Nov 15;19(22):6322-8. doi: 10.1158/1078-0432.CCR-13-1975. Epub 2013 Sep 27.
9
The TARC/sICAM5 Ratio in Patient Plasma is a Candidate Biomarker for Drug Resistant Epilepsy.
Front Neurol. 2013 Jan 3;3:181. doi: 10.3389/fneur.2012.00181. eCollection 2012.
10
A pilot characterization of human lung NSCLC by protein pathway activation mapping.
J Thorac Oncol. 2012 Dec;7(12):1755-1766. doi: 10.1097/JTO.0b013e3182725fc7.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验